Ceftazidime

Kathryn Dzintars, Pharm.D., BCPS, Paul A. Pham, Pharm.D.
Pediatric Dosing Author: Alice Jenh Hsu, PharmD, BCPS, AQ-ID

INDICATIONS

INDICATIONS

INDICATIONS

FDA

FDA

FDA

  • Lower respiratory tract infections including pneumonia caused by P. aeruginosa and other Pseudomonas spp., H. influenzae, Klebsiella spp., Enterobacter spp., P. mirabilis, E. coli, Serratia spp., and Citrobacter spp.
    • Note: cefotaxime or ceftriaxone preferred for S. pneumoniae.
  • Skin and skin-structure infections caused by P. aeruginosa, Klebsiella spp., E. coli,Proteus spp. including P. mirabilisand indole-positive Proteus, Enterobacter spp., and Serratia spp.
  • Complicated and uncomplicated urinary tract infections caused by P. aeruginosa,Enterobacter spp., Proteus spp., including P. mirabilis and indole-positive Proteus, Klebsiella spp. and E. coli
  • Septicemia caused by P. aeruginosa, Klebsiella spp., H. influenzae, E. coli, and Serratia spp.
    • Note: cefotaxime or ceftriaxone preferred for S. pneumoniae.
  • Bone and joint infections caused by P. aeruginosa, Klebsiella spp., and Enterobacter spp.
  • Gynecologic infections (endometritis, pelvic cellulitis, and other GYN infections) caused by E. coli
  • Intra-abdominal Infections, including peritonitis caused by E. coli, Klebsiella spp., and polymicrobial infections caused by aerobic and anaerobic organisms (in combination with metronidazole)
  • Central nervous system infections including meningitis, caused by H. influenzae , N. meningitidis, and P. aeruginosa
    • Note: cefotaxime or ceftriaxone preferred for S. pneumoniae

NON-FDA APPROVED USES

NON-FDA APPROVED USES

NON-FDA APPROVED USES

  • Shunt infections
  • Diabetic foot infection (in combination with clindamycin)

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2025 Unbound Medicine, Inc. All rights reserved